EGI
SGMO

EAM Global Investors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

EAM Global Investors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-87,878
Closed -$1.67M – 180
2018
Q1 		$1.67M Hold
87,878
– – 0.87% 11
2017
Q4 		$1.44M Buy
+87,878
New +$1.31M 0.74% 18

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Global Investors's SGMO Position: Q2 2018 in Review

EAM Global Investors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 87,878 shares — an estimated $1.67M sold.

EAM Global Investors first reported a position in SGMO in Q4 2017 and held it in 2 quarters. The position peaked at $1.67M in Q1 2018. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

  • EAM Global Investors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
  • EAM Global Investors sold 87,878 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $1.67M.
  • EAM Global Investors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 2 quarters.
  • EAM Global Investors's SANGAMO THERAPEUTICS INC position peaked at $1.67M in Q1 2018.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on EAM Global Investors's 13F filing for Q2 2018, filed 3 Aug 2018.